Aerie Pharmaceuticals (NSDQ:AERI) said this week that the FDA approved the company’s once-daily eye drop Rocklatan for the treatment of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The Durham, N.C.-based company’s product is a fixed-dose combination of latanoprost and netarsudil – the active ingredient in Aerie’s first drug, Rhopressa. After winning an […]
Aerie expands drug-delivery tech deal with DSM Biomedical
Aerie Pharmaceuticals (NSDQ:AERI) said today that it expanded its drug-delivery R&D deal with DSM Biomedical. The two companies first joined forces in July last year to evaluate the sustained delivery of certain Aerie drugs using DSM’s polymer technology. Initially, the group was focused on developing drug-delivery tech for people with wet age-related macular degeneration and diabetic […]
Aerie seeks FDA nod for Roclatan once-daily eye drop
Aerie Pharmaceuticals (NSDQ:AERI) said today that it submitted a new drug application to the FDA for its once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The company’s Roclatan product is a fixed-dose combination of two drugs – netarsudil and latanoprost. Aerie’s latest eye drug was proven to be safe and […]
Aerie launches glaucoma drug in U.S.
Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision. “We are pleased to announce the availability in […]
Glooko names digital health veteran as CEO | Personnel Moves – April 17, 2018
Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of corporate development. Johannesson previously served as the chief operating officer of Sharecare, a digital health and wellness platform. Before that he led sales, marketing […]
Aerie misses Q4 earnings estimates by 11¢
Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the eye-drug maker missed earnings expectations on Wall Street with its fourth-quarter and full-year financial results. The Durham, N.C.-based company posted a net loss of -$58.5 million, or -$1.60 per share, for the 3 months ended Dec.31. Adjusted to exclude 1-time items, earnings per share were -$1.38, behind […]
Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. “Proteus has created a compelling solution to a problem that has plagued the pharmaceutical industry for decades: […]
SureFire Medical names pharma vet Szela as president, CEO | Personnel Moves – Jan. 26, 2018
SureFire Medical has named pharma veteran Mary Szela as its president, CEO and board member, succeeding founder James Chomas, who has served as the company’s chief executive and president since 2009. Chomas will assume the role of chief technology officer and oncology strategy officer, focusing his efforts on the the company’s oncology drug-delivery tech. “Immune […]
Aerie Pharmaceuticals prices $75m public offering
Aerie Pharmaceuticals (NSDQ:AERI) has priced an underwritten public offering of $75 million in shares of its common stock. The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock. Aerie reported that it plans to use the net proceeds from the offering to fund […]
Aerie’s glaucoma eye drops win early FDA nod
Aerie Pharmaceuticals (NSDQ:AERI) won an early FDA nod for its glaucoma drug, Rhopressa. The agency was slated to make a decision about the company’s eye drops in February. The win for Aerie came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts […]
